View Older Stories View More Recent Stories

May 31, 2022 07:00AM Zentalis Pharmaceuticals Promotes Cofounder Cam Gallagher to President
May 16, 2022 07:02AM Zentalis Pharmaceuticals (ZNTL) Appoints Kimberly Blackwell as CEO
May 16, 2022 07:00AM Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer
May 5, 2022 07:00AM Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
Apr 11, 2022 04:02PM Zentalis Pharmaceuticals (ZNTL) Overviews Clinical and Preclinical Data
Apr 11, 2022 04:01PM Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR
Apr 8, 2022 01:22PM Zentalis Pharmaceuticals (ZNTL) Announces Initial Clinical Data on ZN-c3 at AACR
Apr 8, 2022 01:00PM Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
Mar 29, 2022 07:03AM Zentalis Pharmaceuticals (ZNTL), Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3
Mar 29, 2022 07:00AM Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3
Mar 22, 2022 07:00AM Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis
Mar 15, 2022 07:00AM STAND UP TO CANCER ANNOUNCES $1 MILLION DONATION FROM ZENTALIS PHARMACEUTICALS TO FUND TARGETED CANCER THERAPY RESEARCH
Mar 9, 2022 04:01PM Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
Mar 8, 2022 04:30PM Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022
Feb 24, 2022 07:00AM Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
Feb 3, 2022 07:00AM Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Dec 2, 2021 07:00AM Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021
Nov 17, 2021 07:01AM Zentalis Pharmaceuticals (ZNTL) Granted Fast Track Designation for ZN-c3 for the Treatment of Uterine Serous Carcinoma
Nov 17, 2021 07:00AM Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma
Nov 10, 2021 07:00AM Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update
Nov 9, 2021 07:00AM Zentalis Pharmaceuticals to Present at Two Upcoming Investor Conferences
Sep 13, 2021 07:00AM Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma
Sep 9, 2021 07:00AM Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2021
Sep 2, 2021 07:00AM Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
Sep 1, 2021 07:00AM Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3
Aug 12, 2021 07:00AM Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update
Aug 4, 2021 07:00AM Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference
Aug 2, 2021 07:30AM Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma
Aug 2, 2021 07:30AM Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma
Aug 2, 2021 07:00AM Zentera Therapeutics Announces Closing of $75 Million Series B Financing
Aug 2, 2021 07:00AM Zentera Therapeutics Announces Closing of $75 Million Series B Financing
Jul 1, 2021 04:01PM Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jun 29, 2021 04:58AM Zentalis Pharmaceuticals (ZNTL) Prices 3.1M Share Offering at $48.50/sh
Jun 28, 2021 09:08PM Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock
Jun 28, 2021 09:08PM Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock
Jun 28, 2021 04:19PM Zentalis Pharmaceuticals (ZNTL) Announces $150M Proposed Public Offering of Common Stock
Jun 28, 2021 04:18PM Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Jun 28, 2021 04:18PM Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
Jun 28, 2021 07:02AM Zentalis Pharmaceuticals (ZNTL) Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c
Jun 28, 2021 07:00AM Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, wit
Jun 28, 2021 07:00AM Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, wit
May 28, 2021 07:00AM Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference
May 17, 2021 07:00AM Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
May 17, 2021 07:00AM Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update
Apr 12, 2021 07:06AM Zentalis Pharmaceuticals (ZNTL) Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline (GSK) to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inh
Apr 12, 2021 07:00AM Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor
Apr 10, 2021 01:30PM Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors
Apr 10, 2021 01:30PM Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors
Mar 25, 2021 07:00AM Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update
Mar 10, 2021 04:37PM Zentalis Pharmaceuticals (ZNTL) Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at AACR
View More Recent Stories View Older Stories